Psoriasis Clinical Trials
There are 155 actively recruiting psoriasis clinical trials across 41 countries. Studies span Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2, Early Phase 1. Top locations include Hangzhou, Zhejiang, China, Toronto, Ontario, Canada, Fountain Valley, California, United States. Updated daily from ClinicalTrials.gov.
Psoriasis Trials at a Glance
155 actively recruiting trials for psoriasis are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Not Applicable with 25 trials, with the heaviest enrollment activity in Hangzhou, Toronto, and Fountain Valley. Lead sponsors running psoriasis studies include Bristol-Myers Squibb, Psoriasis Treatment Center of Central New Jersey, and Cairo University.
Browse psoriasis trials by phase
Top cities for psoriasis trials
Treatments under study
Understanding Psoriasis Clinical Trials
Biologics like adalimumab (Humira), secukinumab (Cosentyx), and guselkumab (Tremfya) — all developed and validated through clinical trials — have transformed psoriasis treatment from managing symptoms to achieving near-complete skin clearance for many patients. More recently, trials of IL-23 inhibitors like risankizumab (Skyrizi) have demonstrated that some patients can maintain clear skin even after stopping treatment, raising the possibility of treatment-free remission. Clinical trials continue to drive progress in psoriasis care, testing next-generation therapies, oral alternatives to injections, and treatments for patients who have not responded to existing biologics.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Psoriasis clinical trials
Many trials require a washout period where you stop your current biologic before starting the study drug. The required washout length varies by trial and by which biologic you are currently taking, typically ranging from four to twelve weeks. Some trials, however, are designed specifically for patients who have failed biologics and may have shorter or no washout requirements. Discuss the timing and safety of any washout period with your dermatologist.
Yes. While many trials focus on moderate-to-severe psoriasis, there are studies testing new topical treatments, phototherapy approaches, and combination regimens for mild disease. Trials for scalp psoriasis, nail psoriasis, and genital psoriasis — specific forms that significantly affect quality of life even when overall body surface area is limited — are also available.
Usually, yes. Most trials require you to discontinue systemic treatments and biologics for a defined washout period before enrollment. Topical treatments like moisturizers and low-potency corticosteroids are often permitted during screening. Your dermatologist can help you plan the transition safely and manage any flares that occur during the washout.
The active treatment phase typically lasts 12 to 52 weeks, with many trials offering an open-label extension period where all participants receive the study drug for an additional one to three years. When a trial ends, your study team will help transition you to an appropriate standard treatment. If the trial drug is later approved, you may be among the first patients prescribed it.
Showing 1–20 of 155 trials